ELISA detection of SARS-CoV-2 antibodies in saliva

To facilitate containment of the COVID-19 pandemic currently active in the United States and across the world, options for easy, non-invasive antibody testing are required. Here we have adapted a commercially available, serum-based enzyme-linked immunosorbent assay (ELISA) for use with saliva sample...

Descripción completa

Detalles Bibliográficos
Autores principales: MacMullan, Melanie A., Ibrayeva, Albina, Trettner, Kylie, Deming, Laura, Das, Sudipta, Tran, Frances, Moreno, Jose Ricardo, Casian, Joseph G., Chellamuthu, Prithivi, Kraft, Jeffrey, Kozak, Kenneth, Turner, Fred E., Slepnev, Vladimir I., Le Page, Lydia M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7705674/
https://www.ncbi.nlm.nih.gov/pubmed/33257702
http://dx.doi.org/10.1038/s41598-020-77555-4
Descripción
Sumario:To facilitate containment of the COVID-19 pandemic currently active in the United States and across the world, options for easy, non-invasive antibody testing are required. Here we have adapted a commercially available, serum-based enzyme-linked immunosorbent assay (ELISA) for use with saliva samples, achieving 84.2% sensitivity and 100% specificity in a set of 149 clinical samples. This strategy will enable widespread, affordable testing for patients who experienced this disease, whilst minimizing exposure risk for healthcare workers.

Ejemplares similares